SEVERE CORONAVIRUS DISEASE 2019: FROM PATHOGENESIS TO THERAPY.
Journal
Shock (Augusta, Ga.)
ISSN: 1540-0514
Titre abrégé: Shock
Pays: United States
ID NLM: 9421564
Informations de publication
Date de publication:
01 03 2023
01 03 2023
Historique:
pubmed:
6
12
2022
medline:
8
3
2023
entrez:
5
12
2022
Statut:
ppublish
Résumé
The COVID-19 pandemic has been a challenge to propose efficient therapies. Because severe SARS-CoV2 infection is a viral sepsis eventually followed by an immunological autoinflammatory phenomenon, many approaches have been inspired by the previous attempts made in bacterial sepsis, while specific antiviral strategies (use of interferon or specific drugs) have been additionally investigated. We summarize our current thinking on the use of SARS-CoV-2 antivirals, corticosteroids, anti-IL-1, anti-IL-6, anti-C5a, as well as stem cell therapy in severe COVID-19. Patient stratification and appropriate time window will be important to be defined to guide successful treatment.
Identifiants
pubmed: 36469709
doi: 10.1097/SHK.0000000000001956
pii: 00024382-202303001-00004
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
10-15Informations de copyright
Copyright © 2023 by the Shock Society.
Références
Osuchowski MF, Winkler MS, Skirecki T, Cajander S, Shankar-Hari M, Lachmann G, Monneret G, Venet F, Bauer M, Brunkhorst FM, et al.: The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 9(6):622–642, 2021.
Leung K, Wu JT, Leung GM: Effects of adjusting public health, travel, and social measures during the roll-out of COVID-19 vaccination: a modelling study. Lancet Public Health 6(9):e674–e682, 2021.
Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, Feldman J, Pavlovic MN, Gregory DJ, Poznansky MC, et al.: Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. Cell 184(9):2372–2383.e9, 2021.
Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP: The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol 20(6):363–374, 2020.
Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, Su X, Cao B: SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet 395(10235):1517–1520, 2020.
Morens DM, Taubenberger JK, Fauci AS: Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 198(7):962–970, 2008.
Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, Soucy JR, Daneman N: Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. Clin Microbiol Infect 26(12):1622–1629, 2020.
Bortolotti D, Gentili V, Rizzo S, Schiuma G, Beltrami S, Strazzabosco G, Fernandez M, Caccuri F, Caruso A, Rizzo R: TLR3 and TLR7 RNA sensor activation during SARS-CoV-2 infection. Microorganisms 9(9):1820, 2021.
Zheng M, Karki R, Williams EP, Yang D, Fitzpatrick E, Vogel P, Jonsson CB, Kanneganti TD: TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat Immunol 22(7):829–838, 2021.
Park A, Iwasaki A: Type I and type III interferons—induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe 27(6):870–878, 2020.
Bastard P, Zhang Q, Zhang SY, Jouanguy E, Casanova JL: Type I interferons and SARS-CoV-2: from cells to organisms. Curr Opin Immunol 74:172–182, 2022.
Osuchowski MF, Aletti F, Cavaillon JM, Flohé SB, Giamarellos-Bourboulis EJ, Huber-Lang M, Relja B, Skirecki T, Szabó A, Maegele M: SARS-CoV-2/COVID-19: evolving reality, global response, knowledge gaps, and opportunities. Shock 54(4):416–437, 2020.
Stolarski AE, Kim J, Zhang Q, Remick DG: Cytokine drizzle—the rationale for abandoning “cytokine storm”. Shock 56(5):667–672, 2021.
Cavaillon JM, Adib-Conquy M, Cloëz-Tayarani I, Fitting C: Immunodepression in sepsis and SIRS assessed by ex vivo cytokine production is not a generalized phenomenon: a review. J Endotoxin Res 7(2):85–93, 2007.
Remy KE, Mazer M, Striker DA, Ellebedy AH, Walton AH, Unsinger J, Blood TM, Mudd PA, Yi DJ, Mannion DA, et al.: Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections. JCI Insight 5(17):e140329, 2020.
Wang N, Zhan Y, Zhu L, Hou Z, Liu F, Song P, Qiu F, Wang X, Zou X, Wan D, et al. Retrospective multicenter cohort study shows early interferon therapy is associated with favorable clinical responses in COVID-19 patients. Cell Host Microbe . 28(3):455–464.e2, 2020.
Van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R, Engel JJ, Wiersinga WJ, Vlaar APJ, Shankar-Hari M, et al.: A guide to immunotherapy for COVID-19. Nat Med 28(1):39–50, 2022.
WHO Working Group on the clinical characterisation and management of COVID-19 infection: A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis 20(8):e192–e197, 2020.
RECOVERY Collaborative Group: Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 396(10259):1345–1352, 2020.
Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, et al; WHO Solidarity Trial Consortium.: Repurposed antiviral drugs for COVID-19—Interim WHO Solidarity trial results. N Engl J Med 384(6):497–5112021.
Horby P, Mafham M, Linsell L, et al.: Effect of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med 384(9):882, 2021.
Barratt-Due A, Olsen IC, Nezvalova-Henriksen K, Kåsine T, Lund-Johansen F, Hoel H, Holten AR, Tveita A, Mathiessen A, Haugli M, et al.: Evaluation of the effects of remdesivir and hydroxychloroquine on viral clearance in COVID-19 : a randomized trial. Ann Intern Med 174(9): 1261–1269, 2021.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, et al.: Remdesivir for the treatment of COVID-19 - final report. N Engl J Med 383(19): 1813–26, 2020.
Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, et al.: Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA 324(11): 1048–57, 2020.
Arribas J, Bhagani S, Lobo S, et al.: Randomized trial of molnupiravir or placebo in patients hospitalized with COVID-19. NEJM Evid 1(2):2021. doi:doi.org/10.1056/EVIDoa2100044.
doi: doi.org/10.1056/EVIDoa2100044
Edalatifard M, Akhtari M, Salehi M, et al.: Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial. Eur Respir J 56(6):2002808, 2020.
Hammond J, Leister-Tebbe H, Gardner A, Abreu A, Bao W, Wisemandle W, Baniecki ML, Hendrick VM, Damle B, Simón-Campos A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med 386:1397–1408, 2022.
Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, et al; RECOVERY Collaborative Group.: Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 384(8):693–704, 2021.
Li Y, Meng Q, Rao X, Wang B, Zhang X, Dong F, Yu T, Li Z, Feng H, Zhang J, et al.: Corticosteroid therapy in critically ill patients with COVID-19: a multicenter, retrospective study. Crit Care 24(1): 698, 2020.
Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, Annane D, Azevedo LCP, Berwanger O, Cavalcanti AB, et al; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.: Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324(13):1330–1341, 2020.
Pulakurthi YS, Pederson JM, Saravu K, Gupta N, Balasubramanian P, Kamrowski S, Schmidt M, Vegivinti CTR, Dibas M, Reierson NL, et al : Corticosteroid therapy for COVID-19: a systematic review and meta-analysis of randomized controlled trials. Medicine 100(20): e25719, 2021.
Tu J, Mo X, Zhang X, Xun J, Chen X, Liu Y, Jing W, Xie T: Effects of different corticosteroid therapy on severe COVID-19 patients: a meta-analysis of randomized controlled trials. Expert Rev Respir Med 16(1):79–89, 2022.
Chaudhuri D, Sasaki K, Karkar A, Sharif S, Lewis K, Mammen MJ, Alexander P, Ye Z, Lozano LEC, Munch MW, et al.: Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis. Intensive Care Med 47 :521–537, 2021.
Li H, Yan B, Gao R, Ren J, Yang J: Effectiveness of corticosteroids to treat severe COVID-19: a systematic review and meta-analysis of prospective studies. Int Immunopharmacol 100:108121, 2021.
Noris M, Benigni A, Remuzzi G: The case of complement activation in COVID-19 multiorgan impact. Kidney Int 98(2):314–322, 2020.
Java A, Apicelli AJ, Liszewski MK, Coler-Reilly A, Atkinson JP, Kim AH, Kulkarni HS: The complement system in COVID-19: friend and foe? JCI Insight 5(15):e140711, 2020.
Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, Klavinskis LS, Sacks S: Rationale for targeting complement in COVID-19. EMBO Mol Med 12(8):e12642, 2020.
Cugno M, Meroni PL, Gualtierotti R, Griffini S, Grovetti E, Torri A, Panigada M, Aliberti S, Blasi F, Tedesco F, et al.: Complement activation in patients with COVID-19: a novel therapeutic target. J Allergy Clin Immunol 146(1): 215–2172020.
Gao T, Hu M, Zhang X, et al.: Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv 2020. doi:10.1101/2020.03.29.20041962.
doi: 10.1101/2020.03.29.20041962
Zelek WM, Cole J, Ponsford MJ, Harrison RA, Schroeder BE, Webb N, Jolles S, Fegan C, Morgan M, Wise MP, et al.: Complement inhibition with the C5 blocker LFG316 in severe COVID-19. Am J Respir Crit Care Med 202(9):1304–1308, 2020.
Carvelli J, Demaria O, Vély F, Batista L, Chouaki Benmansour N, Fares J, Carpentier S, Thibult ML, Morel A, Remark R, et al.: Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis. Nature 588(7836): 146–150, 2020.
Skendros P, Mitsios A, Chrysanthopoulou A, Mastellos DC, Metallidis S, Rafailidis P, Ntinopoulou M, Sertaridou E, Tsironidou V, Tsigalou C, et al.: Complement and tissue factor–enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J Clin Invest 130(11): 6151–6157, 2020.
Vlaar APJ, De Bruin S, Busch M, Timmermans SAMEG, van Zeggeren IE, Koning R, Ter Horst L, Bulle EB, van Baarle FEHP, van de Poll MCG, et al.: Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. Lancet Rheumatol 2(12):e764–e773, 2020.
de Bruin S, Bos LD, Van Roon MA, Tuip-de Boer AM, Schuurman AR, Koel-Simmelinck MJA, Bogaard HJ, Tuinman PR, van Agtmael MA, Hamann J, et al.: Clinical features and prognostic factors in COVID-19: a prospective cohort study. EBioMedicine 67: 103378, 2021.
Ram Kumar Pandian S, Arunachalam S, Deepak V, Kunjiappan S, Sundar K: Targeting complement cascade: an alternative strategy for COVID-19. 3 Biotech 10(11):479, 2020.
Sarma VJ, Huber-Lang M, Ward PA: Complement in lung disease. Autoimmunity 39(5):387–394, 2006.
Rovina N, Akinosoglou K, Eugen-Olsen J, Hayek S, Reiser J, Giamarellos-Bourboulis EJ: Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care 24(1):187, 2020.
Azam TU, Shadid HR, Blakely P, O'Hayer P, Berlin H, Pan M, Zhao P, Zhao L, Pennathur S, Pop-Busui R, et al.: Soluble urokinase receptor (suPAR) in COVID-19-related AKI. J Am Soc Nephrol 31(11): 2725–2735, 2020.
Vasbinder A, Anderson E, Shadid H, Berlin H, Pan M, Azam TU, Khaleel I, Padalia K, Meloche C, O'Hayer P, et al.: Inflammation, hyperglycemia, and adverse outcomes in individuals with diabetes mellitus hospitalized for COVID-19. Diabetes Care 45: 692–700, 2022.
Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G, Gatselis N, Karakike E, Saridaki M, Loli G, Stefos A, et al.: An open label trial of anakinra to prevent respiratory failure in COVID-19. Elife 10:e66125, 2021.
Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, Fragkou A, Rapti A, Damoulari C, Fantoni M, et al.: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nat Med 27(10): 1752–1760, 2021.
Sallenave JM, Guillot L: Innate immune signaling and proteolytic pathways in the resolution or exacerbation of SARS-CoV-2 in COVID-19: key therapeutic targets? Front Immunol 11:1229, 2020.
Galani IE, Rovina N, Lampropoulou V, Triantafyllia V, Manioudaki M, Pavlos E, Koukaki E, Fragkou PC, Panou V, Rapti V, et al.: Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison. Nat Immunol 22(1): 32–40, 2021.
Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, Hirayama AV, Mastroiani F, Turtle CJ, Harhay MO, et al.: Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med 8(12): 1233–1244, 2020.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al.: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229): 1054–1062, 2020.
Zhu J, Pang J, Ji P, Zhong Z, Li H, Li B, Zhang J: Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis. J Med Virol 93(1):35–37, 2021.
Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S, Parkinson N, Fourman MH, Russell CD, et al.: Genetic mechanisms of critical illness in COVID-19. Nature 591(7848):92–98, 2021.
Bovijn J, Lindgren CM, Holmes MV: Genetic variants mimicking therapeutic inhibition of IL-6 receptor signaling and risk of COVID-19. Lancet Rheumatol 2(11):e658–e659, 2020.
Cavaillon JM: Pro- versus anti-inflammatory cytokines: myth or reality. Cell Mol Biol (Noisy-le-grand) 47(4):695–702, 2001.
Zizzo G, Tamburello A, Castelnovo L, Laria A, Mumoli N, Faggioli PM, Stefani I, Mazzone A: Immunotherapy of COVID-19: inside and beyond IL-6 signalling. Front Immunol 13:795315, 2022.
Jones SA, Hunter CA: Is IL-6 a key cytokine target for therapy in COVID-19? Nat Rev Immunol 21(6):337–339, 2021.
RECOVERY Collaborative Group: Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet 397(10285):1637–1645, 2021.
Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D, Beane A, van Bentum-Puijk W, Berry LR, et al; REMAP-CAP Investigators.: Interleukin-6 receptor antagonists in critically ill patients with COVID-19. N Engl J Med 384(16):1491–1502, 2021.
Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, Franceschini E, Cuomo G, Orlando G, Borghi V, et al.: Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol 2(8): e474–e484, 2020.
Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, Horick NK, Healy BC, Shah R, Bensaci AM, et al.: Efficacy of tocilizumab in patients hospitalized with COVID-19. N Engl J Med 383(24): 2333–2344, 2020.
Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, Bruzzi P, Boni F, Braglia L, Turrà C, et al.: Effect of Tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med 181(1): 24–31, 2021.
Rosas IO, Bräu N, Waters M, Go RC, Malhotra A, Hunter BD, Bhagani S, Skiest D, Savic S, Douglas IS, et al.: Tocilizumab in patients hospitalised with COVID-19 pneumonia: efficacy, safety, viral clearance, and antibody response from a randomised controlled trial (COVACTA). EClinicalMedicine 47: 101409, 2022.
Zhao J, Cui W, Tian BP: Efficacy of tocilizumab treatment in severely ill COVID-19 patients. Crit Care 24:524, 2020.
Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G, Benbenishty JS, et al; WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group.: Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA 326(6):499–518, 2021.
Lan SH, Lai CC, Huang HT: Tocilizumab for severe COVID-19: a systematic review and meta-analysis. J Antimicrob Agents 56(3):106103, 2020.
Albuquerque AM, Tramujas L, Sewanan LR, Williams DR, Brophy JM: Mortality rates among hospitalized patients with COVID-19 infection treated with tocilizumab and corticosteroids: a bayesian reanalysis of a previous meta-analysis. JAMA Netw Open 5(2):e220548, 2022.
Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, et al.: Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med 384(9): 795–807, 2021.
Guimaraes PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, Kalil Filho R, Junior VM, Soeiro AM, Tognon AP, et al.: Tofacitinib in patients hospitalized with COVID-19 pneumonia. N Engl J Med 385(5): 406–415, 2021.
Stebbing J, Lauschke VM: JAK inhibitors—more than just glucocorticoids. N Engl J Med 385(5):463–465, 2021.
Byrnes D, Masterson CH, Artigas A, Laffey JG: Mesenchymal stem/stromal cells therapy for sepsis and acute respiratory distress syndrome. Semin Respir Crit Care Med 42(1):20–39, 2021.
Zaki MM, Lesha E, Said K, et al.: Cell therapy strategies for COVID-19: correct approaches and potential applications. Sci Adv 7(33):eabg5995, 2021.
Barros I, Silva A, Pereira de Almeida L, Oliveira Miranda C: Mesenchymal stromal cells to fight SARS-CoV-2: taking advantage of a pleiotropic therapy. Cytokine Growth Factor Rev 58:114–133, 2021.
Mahida RY, Matsumoto S, Matthay M: Extracellular vesicles: a new frontier for research in acute respiratory distress syndrome. Am J Respir Cell Mol Biol 63(1):15–24, 2020.
Dutra Silva J, Su Y, Calfee CS, Delucchi KL, Weiss D, McAuley DF, O'Kane C, Krasnodembskaya AD: Mesenchymal stromal cell extracellular vesicles rescue mitochondrial dysfunction and improve barrier integrity in clinically relevant models of ARDS. Eur Respir J 58(1):2002978, 2021.
Sharma D, Zhao F: Updates on clinical trials evaluating the regenerative potential of allogenic mesenchymal stem cells in COVID-19. Regen Med 6(1):37, 2021.
da Silva KN, Gobatto ALN, Costa-Ferro ZSM, Cavalcante BRR, Caria ACI, de Aragão França LS, Nonaka CKV, de Macêdo Lima F, Lopes-Pacheco M, Rocco PRM, et al.: Is there a place for mesenchymal stromal cell-based therapìes in the therapeutic armamentarium against COVID-19? Stem Cell Res Ther 12(1):425, 2021.